BioAge Labs CMO Paul Rubin liquidates entire 68.9K share stake at $10.19, exiting $701.9K position
Paul Rubin, Chief Medical Officer, executed a complete exit of his equity stake, selling 68,897 shares for $701,908.86 and reducing his post-transaction holdings to 0 shares. The company is operating at significant losses ($-20,171,000.00 net income in the latest period) against quarterly revenue of only $2,054,000.00, indicating BioAge Labs is burning cash substantially faster than it generates sales. The sale occurred at $10.19 on 2025-12-04, below the current market price of $11.61 and well below the 52-week high of $20.09, yet the stock has surged 54.8% over the 30-day prior period despite deteriorating fundamentals. A complete equity liquidation by the CMO—a core scientific and operational leadership role in a clinical/biotech context—represents a decisive shift in insider exposure and warrants investor scrutiny of the company's clinical pipeline status and cash runway expectations.